Noticias y vídeos - GILEAD SCIENCES INC.

Kite, a Gilead Company (Nasdaq: GILD), today announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta ® (axicabtagene ciloleucel) in patients with relapsed/refractory non-Hodgkin lymphomas (NHL) including follicular lymphoma (FL) or marginal zone lymphoma (MZL). The analysis demonstrated that after a median follow-up of more than five years, patients treated with Yescarta continued to experience durable response and long-term survival. The data were shared in...

Kite, a Gilead Company (Nasdaq: GILD), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus ® (brexucabtagene autoleucel) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The data presented include an oral presentation (Abstract # 748) of a primary...

Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta ® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were presented at 66 th American Society of Hematology (ASH) Annual Meeting & Exposition. The data include findings from the largest real-world analysis of patients who received Yescarta as second-line treatment for R/R LBCL during 2022-2023 based...

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203665344/en/ Through this agreement, Gilead will gain access to Tubulis’ proprietary Tubutecan and Alco5 platforms. The companies will collaborate to select the...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine ( NEJM ) published the full results from the company’s pivotal Phase 3 PURPOSE 2 trial evaluating twice-yearly lenacapavir for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. The study found that twice-yearly lenacapavir for pre-exposure prophylaxis (PrEP) was highly efficacious at reducing HIV infections, reducing them by...

NORTHAMPTON, MA / ACCESSWIRE / November 26, 2024 / Women - especially teen girls and young women living in sub-Saharan Africa - are disproportionately impacted by HIV globally, with about 3,100 acquiring HIV each week. They've also historically been excluded from or underrepresented in HIV clinical trials. That's why Gilead's PURPOSE 1 trial, which studied the safety and efficacy of an investigational HIV pre-exposure prophylaxis or PrEP medication, set out to exclusively focus on young African...

actualités #cac40 #bourse #economie #trading #analysetechnique #marchésfinanciers #shorts #short....

actualités #cac40 #bourse #economie #trading #analysetechnique #marchésfinanciers #shorts #short....

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi ® (seladelpar) achieved a composite biochemical response (CBR), demonstrating significant improvements in a key measures of PBC progression. Additionally, 41% (15 out of 37) of participants achieved normalization of alkaline phosphatase (ALP)...

Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of $750 million of 4.80% senior notes maturing in 2029, $1 billion of 5.10% senior notes maturing in 2035, $1 billion of 5.50% senior notes maturing in 2054 and $750 million of 5.60%...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial ( NCT04925752 ), which is studying twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. Newly presented results include data on adherence to and pharmacokinetics of lenacapavir among trial participants....

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed agents with varied dosing frequencies and administration methods. The key findings presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024) reflect a transformative portfolio and future-looking pipeline focused on person-centered drug development...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthcare Conference on Wednesday, November 20 at 9:30 AM Greenwich Mean Time Piper Sandler Annual Healthcare Conference on Tuesday, December 3 at 11:00 AM Eastern Time Annual Evercore ISI HealthCONx Conference on Wednesday, December 4 at 11:40 AM Eastern Time The live webcasts can be accessed at the company’s investors page at investors.gilead.com...

NORTHAMPTON, MA / ACCESSWIRE / October 31, 2024 / Gilead Sciences We're prioritizing health equity for patients across the cancer care continuum. Our Gilead Oncology Grant supports 22 U.S. organizations with $3.15 million to provide resources for people affected by breast cancer. Learn more here: https://gilead.inc/3NM4Vmo Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The...

Expanded agreement includes development of additional transgenic mouse technologies and performance of additional therapeutic antibody research programs FOSTER CITY, CA / ACCESSWIRE / October 31, 2024 / AbTherx, a biotechnology company with innovative technologies that enable and accelerate therapeutic antibody discovery and development, today announced the expansion of a previous agreement with Gilead Sciences, Inc. (Nasdaq:GILD) to develop novel antibody discovery technologies and discover...

NORTHAMPTON, MA / ACCESSWIRE / October 8, 2024 / In the early 2000s, Dr. Shannon Hader led the U.S. Centers for Disease Control and Prevention's collaboration with the Zimbabwe Ministry of Health that provided tens of thousands of people with much-needed HIV care. Shannon, a public health and infectious disease specialist, returned to the United States in 2006 to witness a vastly different situation in the nation's capital. Washington, D.C. was facing a public health crisis with the highest...

Hetero firma un acuerdo de licencia voluntaria con Gilead para transformar la respuesta mundial al VIH, y amplía el acceso al innovador lenacapavir a 120 países de alta incidencia PR Newswire HYDERABAD, India, 3 de octubre de 2024 - Un acuerdo voluntario de licencia no exclusiva permite la fabricación y distribución de lenacapavir, para la prevención del VIH y el tratamiento de pacientes con VIH multirresistente y con amplia experiencia en el tratamiento HYDERABAD, India , 3 de octubre de...

NORTHAMPTON, MA / ACCESSWIRE / September 25, 2024 / Gilead Sciences As a young gay professional, Terrell Parker spent several years working at the National Minority AIDS Council in Washington, D.C. during his 20s, advocating to help end the HIV epidemic and reduce stigma. When Terrell moved back home to Indianapolis, he ran into an issue with his insurance that left him unable to get his prescription for pre-exposure prophylaxis, or PrEP - a once-daily medication that helps prevent HIV...

NORTHAMPTON, MA / ACCESSWIRE / September 18, 2024 / Gilead Sciences Jackson Egen learned the value of basic lab research as a graduate student at UC Berkeley in the 90s while working under the direction of renowned immunologist James Allison. "Jim emphasized that more impactful cancer immunotherapies could come from a detailed understanding of how the immune system works," recalls Jackson, who today serves as Vice President of Research Oncology at Gilead. Not only did James teach fundamentals to...

NORTHAMPTON, MA / ACCESSWIRE / September 12, 2024 / Each scientific discovery gets us one step closer to our shared goal of ending the HIV epidemic. As a leader in HIV treatment and prevention, we'll continue to build on our legacy and create innovative solutions to address the diverse needs of all people affected by HIV. Watch the video to learn more about our work. Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes...